BioProject

Circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. More...

Circulating microRNAs are linked to the onset and progression of type 1 diabetes mellitus (T1DM), making them potential biomarkers for the disease. In this study, we employ a multiplatform sequencing approach to analyze circulating microRNAs in an extended cohort of individuals with T1DM from the INNODIA consortium. Our findings reveal that a set of microRNAs located within the T1DM susceptibility chromosomal locus 14q32 distinguishes two subgroups of individuals. To validate our results, we conduct additional analyses on a second cohort of T1DM individuals, confirming the identification of these subgroups, which we have named Cluster A and Cluster B. Remarkably, Cluster B T1DM individuals, who exhibit increased expression of a set of 14q32 miRNAs, show better glycaemic control and display a different blood immunomics profile. Our findings suggest that this set of circulating microRNAs can identify two different T1DM subgroups with distinct blood immunomics at baseline and clinical outcomes during follow-up. Overall design: The study design involved the analysis of two cohorts of Type 1 Diabetes (T1DM) subjects: an initial screening cohort, the INNODIA first cohort, consisting of n=115 T1DM individuals, and a validation cohort, the INNODIA second cohort, consisting of n=147 T1DM individuals. All subjects were followed-up with programmed visits at 3 (visit 2), 6 (visit 3) and 12 months (visit 4) after clinical diagnosis of T1DM. In both cohorts, blood samples were collected at baseline (visit 1) and processed within 2 hours from blood draw. The collected blood samples underwent centrifugation to separate plasma from contaminant cells and platelets. The plasma samples were then aliquoted (200 μL) and stored at -80°C in a centralized biobank. For the INNODIA first cohort, the plasma samples were subjected to miRNA profiling using two different sequencing platforms: HTG-miRNA Edge Seq and Small RNA-seq. The profiling was followed by validation using droplet digital PCR. For the validation cohort, the plasma samples were analyzed using small RNA-seq, and subsequently validated using droplet digital PCR. Less...